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OPINION 
Medication Needs to be Considered in Biomarker Discovery 
Blood has been used in over 90% of biomarker research, even though urine was proposed to be a better 
biomarker source because urine has no homeostatic mechanisms and contains lots of changes associated with 
diseases [1]. Early changes may be removed from blood because of homeostatic mechanisms. Blood can also be 
used as biomarker source when all the homeostatic mechanisms cannot compensate the changes and new 
homeostatic point was established in blood in the new pathphysiological condition.  
Urine accumulates lots of changes. Its proteome is easily affected by different factors, including medicines [2, 3]. 
I proposed that in urine biomarker studies, the effect of medication needs to be considered [4]. Most biomarker 
laboratories have been working on blood proteome of diseases, but not many studies was seen on the effect of 
medication on blood proteome.  
The effect of anticoagulants studies have shown that medication can make changes in blood proteome even 
though a much bigger changes were seen in urine. In haperin treated group, there were still three proteins changed 
in blood while in agatroban group there was one protein changed. The changes were not trivial changes even 
though they may not be as significant as changes in urine. As most of the biomarker studies were done in blood 
only (instead of what I advocated urine), these changes may be taken as significant changes of the disease without 
realizing they might be the effect of associated medication. The associations of disease - medication and healthy 
control - no medication are all strong associations. If the associations were not taken into consideration of the 
experimental design, big data can not differentiate if the biomarker is disease biomarker or medicine biomarker, no 
matter how big the data is. Clinical validation of biomarker is not cheap. Flaw in design may lead to wrong 
candidate. This is devastating.  
I propose that the effect of medication should be considered in the clinical biomarker design in blood too. Only 
when it is considered, the biomarkers discovered are true disease biomarkers instead of medicine biomarkers which 
are useless. Medicine in blood can be measured directly; it does not need a marker. But studies on effects of 
medicine are valuable. It helps us to avoid costly phony candidates. 
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